- Optimi (OPTI) has signed an agreement with SABI Mind to supply GMP psilocybin and 3,4 Methylenedioxymethamphetamine (MDMA) to its trained clinical staffs
- SABI Mind’s practitioners will use the supplies for psychedelic-assisted therapeutic protocols with approved patients via Health Canada’s Special Access Program, clinical trials, and academic studies
- SABI is a Calgary-based clinic group providing psychedelic-assisted therapies
- Optimi Health focuses on producing and suppling natural, EU-GMP grade psilocybin and functional mushrooms for the health and wellness markets
- Optimi Health Corp. (OPTI) was down 5.08 per cent, trading at C$0.28 per share at 1:00 pm ET
Optimi (OPTI) has signed an agreement with SABI Mind to supply GMP psilocybin and 3,4 Methylenedioxymethamphetamine (MDMA) to its clinical staffs.
SABI Mind’s practitioners will use the supplies for psychedelic-assisted therapeutic protocols with approved patients via Health Canada’s Special Access Program, clinical trials, and academic studies. SABI is a Calgary-based clinic group providing psychedelic-assisted therapies.
Bill Ciprick, CEO of Optimi Health, commented on the announcement.
“This agreement is an important step forward for both parties. SABI Mind’s initiation of this agreement demonstrates a commitment to safe supply for the development and implementation of therapeutic modalities using psilocybin and MDMA.”
Philippe Lucas PhD, President of SABI Mind also provided his comments.
“There’s growing evidence that MDMA and psilocybin assisted therapies can help treat PTSD, depression and other chronic mental health conditions. We’re very pleased to be working with Optimi to ensure a safe, consistent supply of psilocybin and MDMA to SABI patients qualifying under Health Canada’s Special Access Program.”
The agreement is pending the approval of Optimi Health’s previously announced licensing amendment. The company has recently requested an amendment to its Controlled Substance Dealer’s Licence from Health Canada. It will enable the company to utilize its state-of-the-art analytical laboratory to produce synthetic MDMA, among other substances.
Optimi Health focuses on producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms for the health and wellness markets.
Optimi Health Corp. (OPTI) was down 5.08 per cent, trading at C$0.28 per share at 1:00 pm ET.
